20986-87-2

Upstream product

• 21058-55-9 3-aza-17β-acetoxy-A-homo-4α-androsten-4-one 
• 59285-18-6 17β-acetoxy-3-hydroximinoandrost-4-ene 
• 21058-59-3 C₂₁H₃₁NO₃ 
• 1044-89-9 androst-4-ene-3-one-17-ethylene ketal 
• 7745-40-6 3β-hydroxy-17,17-ethylenedioxo-5-androstene 
• 53-43-0 dehydroepiandrosterone 
• 21058-56-0 8-hydroxy-5a,7a-dimethyl-3,4,5,5a,5b,6,7,7a,8,9,10,10a,11,12-tetradecahydrocyclopenta-[5,6]naphtho[1,2-d]azepin-2(10bH)-one 

Downstream Products

• 21058-62-8 3-aza-A-homo-4α-androsten-4,17-dione oxime 
• 5044-10-0 3,17α-diaza-A,D-bishomoandrost-4α-ene-4,17-dione 
• 98149-18-9 C₂₆H₃₁N₃O 
• 105431-62-7 (5aR,5bS,7aS,10aS,10bR)-5a,7a-Dimethyl-8-(phenyl-hydrazono)-4,5,5a,5b,6,7,7a,8,9,10,10a,10b,11,12-tetradecahydro-3H-cyclopenta[5,6]naphtho[1,2-d]azepin-2-one 

Relevant academic research and scientific papers

CYP11B, CYP17, AND/OR CYP21 INHIBITORS

Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. Formula (Z)

Beckmann rearrangement of 3-aza-A-homo-4α-androsten-4,17-dione oxime and 3-oxo-13α-amino-13,17-seco-4-androsten-17-oic 13,17-lactam oxime

Rearragements of 3-aza-A-homo-4α-androsten-4,17-dione oxime produced a mixture of the normal lactam product and the product of a 'second order' cleavage, an unsaturated nitrile. The lactam 3,17α-diaza-A,D-bishomoandrost-4α-ene-4,17-dione was also obtained from the rearrangement of the syn-3-oxo-13α-amino-13,17-seco-4-androsten-17-oic-13,17-lactam oxime. The resolution of syn- and anti-isomers of VIII was effected by column chromatography and their structure was determined by spectral data.